Glassman Patrick M, Villa Carlos H, Marcos-Contreras Oscar A, Hood Elizabeth D, Walsh Landis R, Greineder Colin F, Myerson Jacob W, Shuvaeva Tea, Puentes Laura, Brenner Jacob S, Siegel Don L, Muzykantov Vladimir R
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
Department of Pathology & Laboratory Medicine, Division of Transfusion Medicine & Therapeutic Pathology, Perelman School of Medicine, Philadelphia, Pennsylvania 19104, United States.
Bioconjug Chem. 2022 Jul 20;33(7):1286-1294. doi: 10.1021/acs.bioconjchem.2c00196. Epub 2022 Jun 16.
Engineering drug delivery systems for prolonged pharmacokinetics (PK) has been an ongoing pursuit for nearly 50 years. The gold standard for PK enhancement is the coating of nanoparticles with polymers, namely polyethylene glycol (PEGylation), which has been applied in several clinically used products. In the present work, we utilize the longest circulating and most abundant component of blood─the erythrocyte─to improve the PK behavior of liposomes. Antibody-mediated coupling of liposomes to erythrocytes was tested in vitro to identify a loading dose that did not adversely impact the carrier cells. Injection of erythrocyte targeting liposomes into mice resulted in a ∼2-fold improvement in the area under the blood concentration versus time profile versus PEGylated liposomes and a redistribution from the plasma into the cellular fraction of blood. These results suggest that in vivo targeting of erythrocytes is a viable strategy to improve liposome PK relative to current, clinically viable strategies.
在近50年的时间里,人们一直在致力于研发具有延长药代动力学(PK)特性的药物递送系统。增强药代动力学的金标准是用聚合物包覆纳米颗粒,即聚乙二醇化(PEGylation),这一技术已应用于多种临床使用的产品中。在本研究中,我们利用血液中循环时间最长且含量最丰富的成分——红细胞,来改善脂质体的药代动力学行为。在体外测试了抗体介导的脂质体与红细胞的偶联,以确定不会对载体细胞产生不利影响的负载剂量。将红细胞靶向脂质体注射到小鼠体内后,与聚乙二醇化脂质体相比,血药浓度-时间曲线下面积提高了约2倍,并且药物从血浆重新分布到血液的细胞部分。这些结果表明,相对于目前临床上可行的策略,体内靶向红细胞是改善脂质体药代动力学的一种可行策略。